2025 Q4 -tulosraportti
71 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,75%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 62 | - | - | ||
| 869 | - | - | ||
| 2 790 | - | - | ||
| 1 300 | - | - | ||
| 1 300 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenNYSE - Nasdaq Real Time Price Novo Nordisk A/S (NVO) USD40.81 DKK258,32 At close: 3:59:59 PM EDT Bernstein's concealed price target of 175 DKK for Novo Nordisk will go down in history as one of the most bizarre misjudgments. It's hard not to wonder if the analysis describes the company – or a parallel reality. The difference is not a nuance, but an expression of a significant cognitive dissonance. Bernstein, you are a laughing stock. Good night.
·3 t sitten · MuokattuNovo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and changes gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors", the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who have nevertheless experienced reduced inflammation and scarring in the liver. Understanding the exact biological process is now very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism 14 April https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1
·4 t sittenIs the news twice as good if one publishes it twice?- ·4 t sittenNovo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and alters gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors" the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who nevertheless experienced reduced inflammation and scarring in the liver. That the exact biological process is now understood is very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up for potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism.
·5 t sittenCurrent price 260 ish 💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
71 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,75%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenNYSE - Nasdaq Real Time Price Novo Nordisk A/S (NVO) USD40.81 DKK258,32 At close: 3:59:59 PM EDT Bernstein's concealed price target of 175 DKK for Novo Nordisk will go down in history as one of the most bizarre misjudgments. It's hard not to wonder if the analysis describes the company – or a parallel reality. The difference is not a nuance, but an expression of a significant cognitive dissonance. Bernstein, you are a laughing stock. Good night.
- ·3 t sitten · MuokattuNovo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and changes gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors", the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who have nevertheless experienced reduced inflammation and scarring in the liver. Understanding the exact biological process is now very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism 14 April https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1·4 t sittenIs the news twice as good if one publishes it twice?
- ·4 t sittenNovo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and alters gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors" the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who nevertheless experienced reduced inflammation and scarring in the liver. That the exact biological process is now understood is very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up for potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism.
- ·5 t sittenCurrent price 260 ish 💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 62 | - | - | ||
| 869 | - | - | ||
| 2 790 | - | - | ||
| 1 300 | - | - | ||
| 1 300 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
71 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,75%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenNYSE - Nasdaq Real Time Price Novo Nordisk A/S (NVO) USD40.81 DKK258,32 At close: 3:59:59 PM EDT Bernstein's concealed price target of 175 DKK for Novo Nordisk will go down in history as one of the most bizarre misjudgments. It's hard not to wonder if the analysis describes the company – or a parallel reality. The difference is not a nuance, but an expression of a significant cognitive dissonance. Bernstein, you are a laughing stock. Good night.
- ·3 t sitten · MuokattuNovo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and changes gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors", the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who have nevertheless experienced reduced inflammation and scarring in the liver. Understanding the exact biological process is now very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism 14 April https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1·4 t sittenIs the news twice as good if one publishes it twice?
- ·4 t sittenNovo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and alters gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors" the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who nevertheless experienced reduced inflammation and scarring in the liver. That the exact biological process is now understood is very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up for potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism.
- ·5 t sittenCurrent price 260 ish 💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 62 | - | - | ||
| 869 | - | - | ||
| 2 790 | - | - | ||
| 1 300 | - | - | ||
| 1 300 | - | - |
Välittäjätilasto
Dataa ei löytynyt